AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 401589 — intervention group
Group type: COMPARATOR
Intervention: Castor oil followed by phosphate enema
Number of subjects: 500
Study 401589 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium bisdiocytl sulfosuccinate with magnesium citrate and bisacodyl
Number of subjects: 500
Study 31784483 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated trial arms with genetic variance
Number of subjects: 5851
Study 31784483 — intervention group
Group type: EXPERIMENTAL
Intervention: GBA gene-only simulations
Number of subjects: 5851
Study 31784483 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug effect of -0.5 points in MDS-UPDRS per year
Number of subjects: 5851
Study 30832955 — intervention group
Group type: EXPERIMENTAL
Intervention: Vermont Family Based Approach (VFBA)
Number of subjects: 0
Study 30832955 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 28137734 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroxine treatment
Number of subjects: 123
Study 28137734 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study 27622699 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate (FF) 25 µg once daily
Number of subjects: 593
Study 27622699 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate (FF) 50 µg once daily
Number of subjects: 593
Study 27622699 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate (FF) 100 µg once daily
Number of subjects: 593
Study 27622699 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate (FP) 100 µg twice daily
Number of subjects: 593
Study 27622699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 593
Study 27622699 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate (FF) groups
Number of subjects: 593
Study 23739219 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 400 µg vaginally 4 hours prior to IUD insertion
Number of subjects: 179
Study 23739219 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study 21104041 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (1-hour sessions, 36 sessions over 12 weeks)
Number of subjects: 21
Study 19503006 — intervention group
Group type: EXPERIMENTAL
Intervention: Bazedoxifene 20 mg
Number of subjects: 444
Study 19503006 — intervention group
Group type: EXPERIMENTAL
Intervention: Bazedoxifene 40 mg
Number of subjects: 444
Study 19503006 — intervention group
Group type: COMPARATOR
Intervention: Raloxifene 60 mg
Number of subjects: 444
Study 19503006 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 444
Study 17126767 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 20
Study 17126767 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO diet
Number of subjects: 20
Study 17126767 — intervention group
Group type: COMPARATOR
Intervention: SFA diet
Number of subjects: 20
Study 14660300 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin-alpha (150 U/kg or 250 U/kg, thrice weekly for 12 weeks)
Number of subjects: 41
Study 14660300 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin-alpha (150 U/kg)
Number of subjects: 41
Study 14660300 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin-alpha (250 U/kg)
Number of subjects: 41
Study 11451296 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin treatment
Number of subjects: 8557
Study 11451296 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8557
Study 8918495 — intervention group
Group type: EXPERIMENTAL
Intervention: sargramostim (GM-CSF) 250 micrograms/m2/d SC on days 3 through 15
Number of subjects: 142
Study 8918495 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 142
Study 8918495 — intervention group
Group type: EXPERIMENTAL
Intervention: sargramostim (GM-CSF)
Number of subjects: 142
Study 1757605 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% halobetasol propionate ointment
Number of subjects: 134
Study 1757605 — intervention group
Group type: COMPARATOR
Intervention: 0.05% clobetasol propionate ointment
Number of subjects: 134
Study 6810904 — intervention group
Group type: EXPERIMENTAL
Intervention: bezafibrate
Number of subjects: 16
Study 30869956 — intervention group
Group type: EXPERIMENTAL
Intervention: Response scales with 2 to 5 options
Number of subjects: 1358
Study 30869956 — intervention group
Group type: EXPERIMENTAL
Intervention: Response scales with more than 6 options
Number of subjects: 1358
Study 30869956 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual analog condition
Number of subjects: 1358
Study 30869956 — intervention group
Group type: EXPERIMENTAL
Intervention: Criterion validity results
Number of subjects: 1358
Study 27593901 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental_1 group
Number of subjects: 230
Study 27593901 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental_2 group
Number of subjects: 230
Study 27593901 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 230
Study 25519197 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose probiotics (10^10 cells for 21 days)
Number of subjects: 149
Study 25519197 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose probiotics (10^10 cells for 14 days)
Number of subjects: 149
Study 25519197 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-dose probiotics (10^9 cells for 21 days)
Number of subjects: 149
Study 25519197 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study 24378016 — intervention group
Group type: EXPERIMENTAL
Intervention: 4g/day prescription omega‐3 fatty acid ethyl ester (P‐OM3)
Number of subjects: 61
Study 24378016 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (P‐OM3 + ERN)
Number of subjects: 61
Study 24378016 — intervention group
Group type: COMPARATOR
Intervention: 2g/day extended‐release nicotinic acid (ERN)
Number of subjects: 61
Study 24378016 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 21699447 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic salt sensor and personalized e-mail advice
Number of subjects: 41
Study 21699447 — intervention group
Group type: COMPARATOR
Intervention: Control group (counseled together with intervention group)
Number of subjects: 41
Study 21699447 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 41
Study 19216960 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mm Hg nongraduated sustained pneumatic compression (SPC) for 6 hours
Number of subjects: 28
Study 19216960 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mm Hg graduated intermittent pneumatic compression (IPC) for 2 hours
Number of subjects: 28
Study 19216960 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 to 40 mm Hg graduated SPC for 6 hours
Number of subjects: 28
Study 19216960 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mm Hg graduated IPC for 2 hours
Number of subjects: 28
Study 19216960 — intervention group
Group type: COMPARATOR
Intervention: Baseline profile with no compression
Number of subjects: 28
Study 17208954 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-year smoking prevention programme (14 information lessons about smoking and refusal skills training, integrated into the standard curriculum)
Number of subjects: 1821
Study 17208954 — intervention group
Group type: COMPARATOR
Intervention: Standard health education curriculum (control group)
Number of subjects: 1821
Study 14985932 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg zolpidem
Number of subjects: 36
Study 14985932 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg zolpidem
Number of subjects: 36
Study 14985932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 12488649 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 41
Study 12488649 — intervention group
Group type: COMPARATOR
Intervention: CPAP placebo
Number of subjects: 41
Study 10360287 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical aqueous suppressants
Number of subjects: 41
Study 10360287 — intervention group
Group type: COMPARATOR
Intervention: Control (no topical aqueous suppressants)
Number of subjects: 41
Study 7661062 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 300 mg loading dose
Number of subjects: 0
Study 7661062 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 500 mg loading dose
Number of subjects: 0
Study 7661062 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg loading dose
Number of subjects: 0
Study 7661062 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 40/40 mg combination
Number of subjects: 0
Study 7661062 — intervention group
Group type: EXPERIMENTAL
Intervention: Different combinations of aspirin doses
Number of subjects: 0
Study 2194770 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.1-0.15 mg/kg)
Number of subjects: 41
Study 2194770 — intervention group
Group type: COMPARATOR
Intervention: Diazepam (0.2-0.4 mg/kg)
Number of subjects: 41
Study 498700 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous verapamil
Number of subjects: 28
Study 498700 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 28
Study 31793991 — intervention group
Group type: EXPERIMENTAL
Intervention: Presatovir 200 mg
Number of subjects: 189
Study 31793991 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 189
Study 31793991 — intervention group
Group type: EXPERIMENTAL
Intervention: Presatovir 200 mg (in lymphopenic patients)
Number of subjects: 189
Study 31793991 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in lymphopenic patients)
Number of subjects: 189
Study 30992034 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferred clamping (clamping after at least 2 min)
Number of subjects: 261
Study 30992034 — intervention group
Group type: COMPARATOR
Intervention: Immediate clamping (clamping within 20 s)
Number of subjects: 261
Study 30992034 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (deferred and immediate clamping)
Number of subjects: 261
Study 27836866 — intervention group
Group type: EXPERIMENTAL
Intervention: sipuleucel‐T followed by ADT (started 2 weeks after sipuleucel‐T completion)
Number of subjects: 68
Study 27836866 — intervention group
Group type: EXPERIMENTAL
Intervention: sipuleucel‐T followed by ADT
Number of subjects: 68
Study 27836866 — intervention group
Group type: EXPERIMENTAL
Intervention: sipuleucel‐T with ADT
Number of subjects: 68
Study 25861467 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0
Study 25861467 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 0
Study 25861467 — intervention group
Group type: COMPARATOR
Intervention: Obese T2D subjects
Number of subjects: 0
Study 23993706 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone (0.5 mg/kg BW daily) for 2 weeks
Number of subjects: 146
Study 22290033 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 122
Study 22290033 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug therapy (fluoxetine)
Number of subjects: 122
Study 22290033 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of CBT and fluoxetine (CBT+fluoxetine)
Number of subjects: 122
Study 22290033 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments combined
Number of subjects: 122
Study 19264245 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial pacing (at 70 beats/min)
Number of subjects: 600
Study 19264245 — intervention group
Group type: COMPARATOR
Intervention: Minimal ventricular pacing (at 40 beats/min)
Number of subjects: 600
Study 17447516 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation (VNS)
Number of subjects: 0
Study 17447516 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS)
Number of subjects: 0
Study 15311169 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 0
Study 15311169 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower doses of beta-blockers
Number of subjects: 0
Study 11323149 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg imipramine
Number of subjects: 18
Study 11323149 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mg codeine
Number of subjects: 18
Study 11323149 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 9011574 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetrahydrobiopterin (500 microg/min)
Number of subjects: 13
Study 9011574 — intervention group
Group type: COMPARATOR
Intervention: Control (matched controls, n=13)
Number of subjects: 13
Study 8225629 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% clindamycin hydrochloride gel
Number of subjects: 20
Study 8225629 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 20
Study 2952095 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine (300 mg/day, t.i.d.)
Number of subjects: 19
Study 2952095 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 29100135 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana use
Number of subjects: 307
Study 28095573 — intervention group
Group type: EXPERIMENTAL
Intervention: SB204 2% twice daily
Number of subjects: 213
Study 28095573 — intervention group
Group type: EXPERIMENTAL
Intervention: SB204 4% once daily
Number of subjects: 213
Study 28095573 — intervention group
Group type: EXPERIMENTAL
Intervention: SB204 4% twice daily
Number of subjects: 213
Study 28095573 — intervention group
Group type: COMPARATOR
Intervention: Vehicle once daily
Number of subjects: 213
Study 28095573 — intervention group
Group type: COMPARATOR
Intervention: Vehicle twice daily
Number of subjects: 213
Study 23999592 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic myringoplasty
Number of subjects: 60
Study 23999592 — intervention group
Group type: COMPARATOR
Intervention: Microscopic myringoplasty
Number of subjects: 60
Study 23252284 — intervention group
Group type: EXPERIMENTAL
Intervention: iptakalim
Number of subjects: 110
Study 23252284 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 110
Study 19336536 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol + Enoximone
Number of subjects: 75
Study 19336536 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 75
Study 19336536 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 75
Study 17846933 — intervention group
Group type: EXPERIMENTAL
Intervention: Movina (St John's Wort product, 300 mg Hypericum perforatum, two tablets daily)
Number of subjects: 24
Study 17846933 — intervention group
Group type: COMPARATOR
Intervention: Control (commercially available multivitamin tablet, Vitamineral)
Number of subjects: 24
Study 15151614 — intervention group
Group type: EXPERIMENTAL
Intervention: LAT (lansoprazole 30 mg b.d., amoxycillin 1000 mg b.d., tinidazole 500 mg b.d.)
Number of subjects: 146
Study 15151614 — intervention group
Group type: COMPARATOR
Intervention: LAC (lansoprazole 30 mg b.d., amoxycillin 1000 mg b.d., clarithromycin 500 mg b.d.)
Number of subjects: 146
Study 12236273 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone call from the practice receptionist offering an appointment for influenza immunisation
Number of subjects: 1820
Study 12236273 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 1820
Study 9841945 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotton pledge soaked in saline (middle nasal meatus stimulation)
Number of subjects: 0
Study 9841945 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotton pledge soaked in 5% cocaine solution (middle nasal meatus stimulation)
Number of subjects: 0
Study 9841945 — intervention group
Group type: COMPARATOR
Intervention: Cotton pledge soaked in saline (control group, inferior nasal concha stimulation)
Number of subjects: 0
Study 7986255 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg cyclandelate
Number of subjects: 24
Study 2545437 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced phytate bran
Number of subjects: 3
Study 2545437 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard bran
Number of subjects: 3
Study 2545437 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice Krispies (low phytate, low fibre cereal)
Number of subjects: 3
Study 2545437 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard bran with histidine
Number of subjects: 3
Study 6326785 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium
Number of subjects: 21
Study 6326785 — intervention group
Group type: COMPARATOR
Intervention: Neostigmine
Number of subjects: 21
Study 31942818 — intervention group
Group type: EXPERIMENTAL
Intervention: Constraint-Induced Movement Therapy (CIMT)
Number of subjects: 20
Study 31942818 — intervention group
Group type: COMPARATOR
Intervention: Hand-Arm Bimanual Intensive Therapy (HABIT)
Number of subjects: 20
Study 30948610 — intervention group
Group type: EXPERIMENTAL
Intervention: Sudarshan Kriya Yoga (SKY) breathing meditation
Number of subjects: 0
Study 30948610 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 0
Study 27611301 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS treatment (10 sessions over the bilateral dorsolateral prefrontal cortex)
Number of subjects: 14
Study 26169948 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback (FB) about patients' progress using the OQ®‐Analyst system
Number of subjects: 259
Study 26169948 — intervention group
Group type: COMPARATOR
Intervention: No feedback (NFB)
Number of subjects: 259
Study 25108889 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening (PSA testing)
Number of subjects: 13515
Study 25108889 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 13515
Study 22412073 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention promoting weight loss and hypertension self-management using eHealth components (tailored behavior change goals, self-monitoring, skills training, 18 telephone counseling calls, primary care provider endorsement, 12 optional group support sessions, links with community resources)
Number of subjects: 365
Study 22412073 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 365
Study 20956906 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral resection of prostate (TURP)
Number of subjects: 68
Study 17386092 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 grams/day concentrated oat beta-glucan
Number of subjects: 75
Study 17386092 — intervention group
Group type: COMPARATOR
Intervention: 6 grams/day dextrose (control)
Number of subjects: 75
Study 16304291 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (400 mg qd)
Number of subjects: 394
Study 16304291 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin (500 mg qd)
Number of subjects: 394
Study 16304291 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 394
Study 16304291 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin
Number of subjects: 394
Study 12138952 — intervention group
Group type: EXPERIMENTAL
Intervention: AHA step 1 diet for 8 to 10 weeks
Number of subjects: 4257
Study 12138952 — intervention group
Group type: COMPARATOR
Intervention: Labile LDL-C levels (LI and LD groups)
Number of subjects: 4257
Study 12138952 — intervention group
Group type: COMPARATOR
Intervention: Stable LDL-C levels (LN group)
Number of subjects: 4257
Study 9794155 — intervention group
Group type: EXPERIMENTAL
Intervention: Mono‐Tildiem LP 300 (300 mg)
Number of subjects: 16
Study 9794155 — intervention group
Group type: EXPERIMENTAL
Intervention: Adizem XL (300 mg)
Number of subjects: 16
Study 9794155 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardizem (300 mg)
Number of subjects: 16
Study 9794155 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilacor (240 mg)
Number of subjects: 16
Study 8605713 — intervention group
Group type: EXPERIMENTAL
Intervention: 14 gauge needles at QB 500 cc/min
Number of subjects: 21
Study 8605713 — intervention group
Group type: EXPERIMENTAL
Intervention: 17 gauge needles at QB 500 cc/min
Number of subjects: 21
Study 8605713 — intervention group
Group type: EXPERIMENTAL
Intervention: 14 gauge needles at QB 200 cc/min
Number of subjects: 21
Study 8605713 — intervention group
Group type: EXPERIMENTAL
Intervention: 17 gauge needles at QB 200 cc/min
Number of subjects: 21
Study 8605713 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 gauge needles
Number of subjects: 21
Study 8605713 — intervention group
Group type: EXPERIMENTAL
Intervention: 14 gauge needles
Number of subjects: 21
Study 8605713 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 gauge needles
Number of subjects: 21
Study 8605713 — intervention group
Group type: EXPERIMENTAL
Intervention: 17 gauge needles
Number of subjects: 21
Study 2671072 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week supplemental behavioral skills training course (n = 70)
Number of subjects: 130
Study 2671072 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 60)
Number of subjects: 130
Study 322834 — intervention group
Group type: EXPERIMENTAL
Intervention: Maprotiline
Number of subjects: 21
Study 322834 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 21
Study 31583805 — intervention group
Group type: EXPERIMENTAL
Intervention: Responsive treatment
Number of subjects: 50
Study 31583805 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 50
Study 30864970 — intervention group
Group type: EXPERIMENTAL
Intervention: Merino wool clothing
Number of subjects: 0
Study 30864970 — intervention group
Group type: COMPARATOR
Intervention: Standard clothing
Number of subjects: 0
Study 28235526 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine 100 μg/min
Number of subjects: 40
Study 28235526 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine 5 mg/min
Number of subjects: 40
Study 26032587 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydromyricetin (150 mg, two capsules twice daily for three months)
Number of subjects: 60
Study 26032587 — intervention group
Group type: COMPARATOR
Intervention: Placebo (150 mg, two capsules twice daily for three months)
Number of subjects: 60
Study 22891750 — intervention group
Group type: EXPERIMENTAL
Intervention: Twin Force Bite Corrector (TFBC)
Number of subjects: 43
Study 22891750 — intervention group
Group type: COMPARATOR
Intervention: Control (nontreated patients)
Number of subjects: 43